China Universal Asset Management Co., Ltd. Chinook Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$700 Million
Q2 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 21, 2024	SELL	$18.66 - $38.58 $298 - $617	-16 Reduced 1.79%	876 $33,000
Q2 2023 Jul 27, 2023	SELL	$18.66 - $38.58 $298 - $617	-16 Reduced 1.79%	876 $34,000
Q1 2023 May 21, 2024	BUY	$21.53 - $26.8 $5,231 - $6,512	243 Added 37.44%	892 $20,000
Q1 2023 Apr 27, 2023	BUY	$21.53 - $26.8 $5,231 - $6,512	243 Added 37.44%	892 $21,000
Q4 2022 May 21, 2024	BUY	$18.63 - $27.35 $12,090 - $17,750	649 New	649 $17,000
Q4 2022 Jan 31, 2023	BUY	$18.63 - $27.35 $1,117 - $1,641	60 Added 10.19%	649 $17,000
Q3 2022 Oct 21, 2022	BUY	$17.51 - $23.37 $10,313 - $13,764	589 New	589 $12,000

Others Institutions Holding KDNY

# of Institutions

Shares Held

234K

Call Options Held

Put Options Held

View Full List

About CHINOOK THERAPEUTICS, INC.

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

More about KDNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account